US2894960A - 3alpha-succinoxy-11-hydroxy-12-keto-delta9,(11)-cholenic acid and its derivatives - Google Patents
3alpha-succinoxy-11-hydroxy-12-keto-delta9,(11)-cholenic acid and its derivatives Download PDFInfo
- Publication number
- US2894960A US2894960A US642331A US64233157A US2894960A US 2894960 A US2894960 A US 2894960A US 642331 A US642331 A US 642331A US 64233157 A US64233157 A US 64233157A US 2894960 A US2894960 A US 2894960A
- Authority
- US
- United States
- Prior art keywords
- acid
- keto
- hydroxy
- succinoxy
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000003839 salts Chemical class 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 13
- -1 ALKALI METAL SALTS Chemical class 0.000 claims description 7
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 239000002253 acid Substances 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000003312 cholesterol blood level Effects 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HIAJCGFYHIANNA-QIZZZRFXSA-N 3b-Hydroxy-5-cholenoic acid Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 HIAJCGFYHIANNA-QIZZZRFXSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- QJRDZMMIVLVWOR-NFMLMGQYSA-N (8R,9S,10R,13R,14S,17R)-7-hydroxy-13-methyl-15,16-dioxo-17-[(2R)-pentan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carboxylic acid Chemical compound OC1[C@H]2[C@@H]3C(C([C@@H]([C@]3(CC[C@@H]2[C@]2(CCCCC2C1)C(=O)O)C)[C@H](C)CCC)=O)=O QJRDZMMIVLVWOR-NFMLMGQYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- YHTRVWPOAJKWBV-OAFMNPBWSA-N methyl (4r)-4-[(8r,9s,10s,13r,14s,17r)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC(=O)OC)[C@@]1(C)CC2 YHTRVWPOAJKWBV-OAFMNPBWSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000007331 pathological accumulation Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Definitions
- the present invention relates to new derivatives of dihydroxy keto cholenic acid and more particularly to 3- succinoxy-ll-hydr0xy-12-keto-A -cholenic acid and its salts, and to a process of making same.
- Another object of the present invention is to provide a simple and eifective process of making said 3-succinoxy- 1l-hydroxy-l2-keto-A -cholenic acid and its salts.
- Still another object of the present invention is to provide a therapeutically useful preparation for modifying the lipoprotein equilibrium of the serum which preparation is characterized by a content of 3-succinoxy-11-hydroxy-l2-keto-A -cholenic acid or, respectively, its salts
- the present invention deals with the enolic form of said acid, namely with 3-succinoxy-11-hydroxy- 12-keto-A -cholenic acid of Formula 1.
- the new acid is preferably obtained according to the present invention by treating 3u,l1-dihydroxy-12-keto- A -cholenic acid in solution in a suitable solvent with an agent capable of introducing the succinic acid group, such as succinic acid anhydride, in the presence of a condensing agent, such as a tertiary base, for instance, pyridine, and isolating the resulting 3a-succinoXy-ll-hydroxy- 12-keto-A -cholenic acid.
- an agent capable of introducing the succinic acid group such as succinic acid anhydride
- a condensing agent such as a tertiary base, for instance, pyridine
- the 3oz succinoxy ll-hydroxy-12-keto-A -cholenic acid is preferably used in the form of its salts which are highly soluble in water such as salts with an inorganic or organic base.
- the free acid or its salts with bases are administered in the form of capsules, pellets, tablets, dragees, or other preparations permitting oral administration.
- a preferred method of introducing the succinyl group into the 3u,ll-dihydroxy-12-keto-A -cholenic acid consists in dissolving said acid in pyridine which serves as solvent as well as a condensing agent, adding to said solution succinic acid anhydride, heating the mixture for one to two hours at a temperature of about C., and isolating 3a-succinoxy-ll-hydroxy-l2-ketoA -cholenic acid by the conventional methods of Washing, extraction, and crystallization.
- the salts of the resulting 3a-succinoxy-11-hydroxy-l2- keto-A -cholenic acid are prepared by neutralizing a solution of said acid in a suitable solvent by means of a selected inorganic or organic base.
- the resulting salt is separated by centrifuging, filtration, or evaporation to dryness of the reaction medium.
- 3oc,11-dihydroxy-l2keto-A -cholenic acid by any other process than that of the above cited reference, for instance, by alkaline hydrolysis of a derivative of 3a-hydroxy-l1,12- diketocholanic acid, such as 3a-acetoxy-ll,l2-diketo cholanic acid methyl ester, 3ot-formyloxy-l1,12-diketo cholanic acid, or 3u-succinoxy-11,l2-diketo cholanic acid.
- a derivative of 3a-hydroxy-l1,12- diketocholanic acid such as 3a-acetoxy-ll,l2-diketo cholanic acid methyl ester, 3ot-formyloxy-l1,12-diketo cholanic acid, or 3u-succinoxy-11,l2-diketo cholanic acid.
- Especially suitable salts with organic bases are salts obtained by reaction with alkanolamines such as ethanolamine, diethanolamine, triethanola'min'e, ethylene diamine.
- the new acid and its salts are orally effective therapeutic agents for reducing a high cholesterol blood level and normalizing 'same.
- the compounds are preferably administered in the form of tablets, pellets, pills, dragees, powders, solutions, emulsions, suspensions, or other orally administrable preparations.
- the new compounds are preferably used in their dilute form, thus, allowing better and more economical use to be made thereof.
- a fine uniform dispersion of the active product throughout said powder is desirable.
- a fine dispersion can be achieved, for instance, by intimately mixing 4 and milling the compound in a ball mill with a solid, pulverulent extending agent to the desired degree of fineness, or by impregnating the already milled, finely powdered solid carrier with a mixture of the active compound in water or other suitable solvents and then removing the water or solvent.
- the commonly used diluting agents, binders, lubricants and the like tableting adjuvants are employed, such as sugar, lactose, talc, starch, bolus alba, as binders pectin, gelatin, gum arabic, methyl cellulose, yeast extract, agar, tragacanth, and as lubricants stearic acids, magnesium stearate, talc, and others.
- the content of active compound in such preparations may vary. It is, of course, of advantage, that the active compound be present in said preparations in such an amount that a suitable dosage will be ensured.
- the unit dose should contain not less than 10% of the active compound.
- the preferred amounts tobe employed in tablets and the like shaped solid preparations are between about 10% and about 50% of the weight of the unit. To use greater amounts, is, of course, also possible, although administration of suitable doses becomes somewhat cumbersome.
- the maximum single dose is about 500 mg. and the maximum daily dose is about 1500 mg.
- the preferred single dose is between about 100 mg. and about 300 mg. and the preferred daily dose is between about 200 mg. and about 1000 mg.
- Administration of the new acid and its salts is continued until the cholesterol blood level is substantially normal.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
United States Patent 3ot-SUCCINOXY-lI-HYDROXY-IZ-KETO-A 1 CHOLENIC ACID AND ITS DERIVATIVES Julien Warnant, Neuilly-sur-Seine, Gerard Noe, Noisy -le-Sec, and Genevieve Rousseau, Errghien-les- Bains, France, assignors to Les Laboratoires Francais de Chimiotherapie, Paris, France, a body of France N Drawing. Application February 26, 1957 Serial No. 642,331
Claims priority, application France February 29, 1956 3 Claims. (Cl. 260-3971) The present invention relates to new derivatives of dihydroxy keto cholenic acid and more particularly to 3- succinoxy-ll-hydr0xy-12-keto-A -cholenic acid and its salts, and to a process of making same.
It is one object of the present invention to provide a new derivative of a dihydroxy keto cholenic acid and more particularly to provide 3-succinoxy-l1-hydroxy-12- keto-A -cholenic acid and salts thereof, which compounds have proved to be valuable agents in modifying the lipoprotein equilibrium of the serum.
Another object of the present invention is to provide a simple and eifective process of making said 3-succinoxy- 1l-hydroxy-l2-keto-A -cholenic acid and its salts.
Still another object of the present invention is to provide a therapeutically useful preparation for modifying the lipoprotein equilibrium of the serum which preparation is characterized by a content of 3-succinoxy-11-hydroxy-l2-keto-A -cholenic acid or, respectively, its salts Other objects of the present invention and advantageous features thereof will become apparent as the description proceeds.
It is known that normal serum contains, as an average, between 1.5% and 2.0% of total cholesterol, i.e. of free cholesterol and esterified cholesterol. These figures have the tendency to increase in the course of the evolution of certain nutritional disorders or because of certain diseases such as atherosclerosis. It is, therefore, of great importance, to place at the disposal of the medical profession an agent which is capable of reducing, at least to a certain extent, pathological accumulations and concentrations of cholesterol in the blood.
In our co-pending application Serial No. 591,278, filed June 14, 1956, and entitled New Derivative of a Hydroxy-Diketocholanic Acid and a Method of Preparing Same, compounds have been described which are capable of progressively decreasing the cholesterol content of the blood when injected intravaneously. The preferred compound for said purpose is 3-succinoxy-11,12-diket0cholanic acid.
In principle the present invention deals with the enolic form of said acid, namely with 3-succinoxy-11-hydroxy- 12-keto-A -cholenic acid of Formula 1.
CH CH O 0 CH2 COO 3132 OOH Said acid, especially in the form of its salts with suitable bases, permits, by oral administration, to restore quite rapidly the cholesterol content of the blood of chickens which had previously been increased by the application of a feed rich in oil and cholesterol, to its normal cholesterol content. Such a favorable result is achieved when treating chickens having an increased cholesterol blood level for a few weeks with said acid. The treatment has the further advantage that the values obtained in the Kunkel test are lowered and that the plasma is clarified. The toxicity of 3-succinoxy-1l-hydroxy-12-keto-A cholenic acid is remarkably low.
The new acid is preferably obtained according to the present invention by treating 3u,l1-dihydroxy-12-keto- A -cholenic acid in solution in a suitable solvent with an agent capable of introducing the succinic acid group, such as succinic acid anhydride, in the presence of a condensing agent, such as a tertiary base, for instance, pyridine, and isolating the resulting 3a-succinoXy-ll-hydroxy- 12-keto-A -cholenic acid.
The 3oz succinoxy ll-hydroxy-12-keto-A -cholenic acid is preferably used in the form of its salts which are highly soluble in water such as salts with an inorganic or organic base. The free acid or its salts with bases are administered in the form of capsules, pellets, tablets, dragees, or other preparations permitting oral administration.
A preferred method of introducing the succinyl group into the 3u,ll-dihydroxy-12-keto-A -cholenic acid consists in dissolving said acid in pyridine which serves as solvent as well as a condensing agent, adding to said solution succinic acid anhydride, heating the mixture for one to two hours at a temperature of about C., and isolating 3a-succinoxy-ll-hydroxy-l2-ketoA -cholenic acid by the conventional methods of Washing, extraction, and crystallization.
The salts of the resulting 3a-succinoxy-11-hydroxy-l2- keto-A -cholenic acid are prepared by neutralizing a solution of said acid in a suitable solvent by means of a selected inorganic or organic base. The resulting salt is separated by centrifuging, filtration, or evaporation to dryness of the reaction medium.
30 11 dihydroxy l2-keto A -cholenic acid, which serves as starting material for carrying out the process according to the present invention, is obtained according to Wintersteiner and Moore, Journal Biological Chemistry, volume 162, page 731 (1946).
The following examples serve to illustrate the present invention and especially the process of making said acid and its salts without, however, limiting the same thereto. It is, of course, possible to vary the solvents, reactants, reaction conditions, temperature and duration, and the like without departing from the principles of the present invention as they are set forth herein and in the claims annexed hereto. It is also possible to prepare 3oc,11-dihydroxy-l2keto-A -cholenic acid by any other process than that of the above cited reference, for instance, by alkaline hydrolysis of a derivative of 3a-hydroxy-l1,12- diketocholanic acid, such as 3a-acetoxy-ll,l2-diketo cholanic acid methyl ester, 3ot-formyloxy-l1,12-diketo cholanic acid, or 3u-succinoxy-11,l2-diketo cholanic acid.
EXAMPLE 1 Succinylation of 3a,]1-dihydroxy-12-keto-A -cholenic acid -15 g. of 30,11-dihydroxy-12-keto-A -cholenic acid and 4.1 g. of succinic acid anhydride are dissolved in 15 cc. of anhydrous pyridine. The solution is stirred at a temperature of 95 C. for one hour. The resulting reaction mixture is cooled to 30 C. and is then poured, while stirring, into a mixture of 225 cc. of ice-water and 25 cc.
of concentrated hydrochloric acid. The mixture is allowed to stand overnight at room temperature, filtered, washed with water, dried, and re-crystallized from 3 parts by volume of 50% acetic acid, yielding thereby 3oc-SUC- oinoxy-l l-hydroxy-l2-keto-A -cholenic acid with a yield of 72% of the theoretical yield. Melting point: 240 C.; rotary power -[aJ =+87:2 (concentration: 0.5% in acetone). The acid is obtained in the form of colorless crystals which are insoluble in ether, benzene, and chloroform and slightly soluble in water, acetone, and cold ethanol. Its alcoholic solution yields an intense green color with ferric chloride due to its enolic structure. It exhibits an ultraviolet absorption maximum at 281 mg characteristic for B-unsaturated a-hydroxy-ketones.
EXAMPLE 2 Di-sodium salt of 3a-succin0xy-11-hydr0xy- J2-ket0-A -chlenic acid 5 g. of 3a-succ'in'oxy-ll-hydroxy-12-keto-A -cholenic acid are suspended at 65 C. in 10 cc. of water. The suspension is stirred, carbon dioxide is bubbled therethrough, and 33 cc. of an aqueous solution of sodium bicarbonate is added in small portions thereto. The resulting solution is evaporated to dryness in a vacuum at a temperature of 4550 C.; 5.4 g. of-the disodium salt of 3a-succinoxy- 1l-hydroxy-12-keto-A -cholenic acid are obtained. The salt forms a white powder, soluble to about 25% in water at 20 C. and having a rotatory power [a] =-|-90i2 (concentration: 1% in water).
When using, in place of-sodium bicarbonate equimolecular amounts of potassium bicarbonate, and proceeding otherwise in the same manner 'as described in Example 2, the corresponding potassium salts are obtained.
Especially suitable salts with organic bases are salts obtained by reaction with alkanolamines such as ethanolamine, diethanolamine, triethanola'min'e, ethylene diamine.
As stated above, the new acid and its salts are orally effective therapeutic agents for reducing a high cholesterol blood level and normalizing 'same.
The compounds are preferably administered in the form of tablets, pellets, pills, dragees, powders, solutions, emulsions, suspensions, or other orally administrable preparations. The new compounds are preferably used in their dilute form, thus, allowing better and more economical use to be made thereof.
In the administration of such compounds in capsules as powders, a fine uniform dispersion of the active product throughout said powder is desirable. Such a fine dispersion can be achieved, for instance, by intimately mixing 4 and milling the compound in a ball mill with a solid, pulverulent extending agent to the desired degree of fineness, or by impregnating the already milled, finely powdered solid carrier with a mixture of the active compound in water or other suitable solvents and then removing the water or solvent.
When preparing tablets, pills, dragees, and the like shaped solid preparations for oral administration, the commonly used diluting agents, binders, lubricants and the like tableting adjuvants are employed, such as sugar, lactose, talc, starch, bolus alba, as binders pectin, gelatin, gum arabic, methyl cellulose, yeast extract, agar, tragacanth, and as lubricants stearic acids, magnesium stearate, talc, and others.
The content of active compound in such preparations may vary. It is, of course, of advantage, that the active compound be present in said preparations in such an amount that a suitable dosage will be ensured. The unit dose should contain not less than 10% of the active compound. The preferred amounts tobe employed in tablets and the like shaped solid preparations are between about 10% and about 50% of the weight of the unit. To use greater amounts, is, of course, also possible, although administration of suitable doses becomes somewhat cumbersome. The maximum single dose is about 500 mg. and the maximum daily dose is about 1500 mg. The preferred single dose is between about 100 mg. and about 300 mg. and the preferred daily dose is between about 200 mg. and about 1000 mg. Administration of the new acid and its salts is continued until the cholesterol blood level is substantially normal.
It is, of course, also possible to add the acid and its salts to food, especially to the fats used in preparing meals, or
- to flour used in preparing bread and other baked goods.
We claim:
1. A compound selected from the group consisting of 3a-succinoxy-l1-hydroxy-12-keto-A -cholenic acid and its alkali metal salts and salts with' lower alkanol amines and ethylene diamine, said salts being tolerated by the human system.
2. 3 a-succinoxy-l l-hydroxy-l2-keto-A -cholenic acid.
3. The disodium salt of 3a-succinoxy-1l-hydroxy-lZ- keto-rl -cholenic acid.
References Cited in'the file of this patent UNITED STATES PATENTS 2,745,829 Archer May 15, 1956
Claims (1)
1. A COMPOUND SELECTED FROM THE GROUP CONSISTING OF 3A-SUCCINOXY-11-HYDROXY-12-KETO-$9,11-CHOLENIC ACID AND ITS ALKALI METAL SALTS AND SALTS WITH LOWER ALKANOL AMINES AND ETHYLENE DIAMINE, SAID SALTS BEING TOLERATED BY THE HUMAN SYSTEM.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2894960X | 1956-02-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2894960A true US2894960A (en) | 1959-07-14 |
Family
ID=9689703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US642331A Expired - Lifetime US2894960A (en) | 1956-02-29 | 1957-02-26 | 3alpha-succinoxy-11-hydroxy-12-keto-delta9,(11)-cholenic acid and its derivatives |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2894960A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3066084A (en) * | 1959-08-10 | 1962-11-27 | Jones & Laughlin Steel Corp | Ultrasonic pickling |
| US3127314A (en) * | 1964-03-31 | Method of reducing hyperlipemia by |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2745829A (en) * | 1954-03-25 | 1956-05-15 | Sterling Drug Inc | Preparation of 3-hydroxy-11-ketocholanic acid, derivatives and analogs thereof, and intermediates in said preparation |
-
1957
- 1957-02-26 US US642331A patent/US2894960A/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2745829A (en) * | 1954-03-25 | 1956-05-15 | Sterling Drug Inc | Preparation of 3-hydroxy-11-ketocholanic acid, derivatives and analogs thereof, and intermediates in said preparation |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3127314A (en) * | 1964-03-31 | Method of reducing hyperlipemia by | ||
| US3066084A (en) * | 1959-08-10 | 1962-11-27 | Jones & Laughlin Steel Corp | Ultrasonic pickling |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1280369C (en) | Pharmaceutical with anti-tumor effect | |
| US5190947A (en) | Codeine salt of a substituted carboxylic acid, its use and pharmaceutical compositions thereof | |
| IE47884B1 (en) | Xanthine derivatives having antiallergic activity and pharmacological preparations containing them | |
| JPS6023102B2 (en) | Novel epinin ester, its production method and pharmaceutical composition | |
| DE68910211T2 (en) | Estramustine ester. | |
| DE2418344A1 (en) | MEDICINAL PRODUCTS CONTAINING DERIVATIVES OF 3-NITROCUMARINES, NEW 3-NITROCUMARINES AND METHODS FOR THEIR MANUFACTURING | |
| US2894960A (en) | 3alpha-succinoxy-11-hydroxy-12-keto-delta9,(11)-cholenic acid and its derivatives | |
| EP0074411B1 (en) | Ascorbic acid derivatives | |
| CA1038402A (en) | Therapeutic agents | |
| EP0100516B1 (en) | 3-beta-(3'-(carboxypropionyloxy))-ursa-9(11),12-dience-28-carboxylic acid and its salts, process for its preparation and medicines containing these compounds | |
| KR900006760B1 (en) | Substituted anilides of oleic linoeic or linolenic acid as inhibitors of acyl-coai cholesterol acyltransferase | |
| US3718655A (en) | Certain diisoniazid methane sulfonate complexes | |
| US3935196A (en) | Useful pro-drug forms of theophylline | |
| BE1001251A4 (en) | Pharmaceutical composition containing organic complex zinc and method for preparing the active product. | |
| US4002756A (en) | Useful pro-drug forms of theophylline | |
| JPS63295561A (en) | 2-quinolone derivative | |
| DE69323998T2 (en) | PHARMACEUTICAL ACTIVE FLAVILIUM COMPOUNDS | |
| US4218447A (en) | Acyl derivatives of hellebrigenin | |
| EP0767777A1 (en) | New salts of 2- (2,6-dichlorophenyl)amine]phenylacetoxyacetic acid with organic basic cations | |
| US4423053A (en) | Derivatives of 2-amino-5-(o-sulphamidophenyl)-1,3,4-thiadiazol as antiviral agents and a process for the preparation thereof | |
| US3882127A (en) | 17-alkenyl-6{62 -azido-4,5{60 -epoxymorphinan-3-ols | |
| KR810001697B1 (en) | Novel Method for Preparing Isobutyramid Derivatives | |
| US4758591A (en) | Dialkanoyloxybenzylidene dialkanoate | |
| US4820837A (en) | 1-hydroxy-oxo-5H-pyrido(3,2-a)phenoxazine-3-carboxylic acid esters | |
| EP0158170B1 (en) | Erythromycin a salt with mucosecretolytic and fluidizing activity, a process for its preparation and pharmaceutical compositions thereof |